EAGAN, MN / ACCESSWIRE / September 24, 2020 / Dynatronics Corporation (NASDAQ:DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced financial results for its fourth quarter and fiscal year ended June 30, 2020.
“Our fourth quarter and year ending results were negatively impacted by COVID-19, but our team continues to improve operational effectiveness in an effort to leverage our expense structure and manage working capital,” stated John Krier, CEO of Dynatronics Corporation. “Despite a revenue decrease for fiscal year 2020, we are taking decisive actions to prepare the Company for future growth opportunities.”
Fiscal 2020 Fourth Quarter Financial Results
Net sales for the quarter ended June 30, 2020 were $8.1 million, a decrease of $7.4 million, or 47.7%, compared to $15.5 million in the same period of the prior year. Gross profit for the quarter decreased $3.1 million, or 68.9%, to $1.4 million. The decrease in net sales and gross profit were primarily attributable to stay-at-home policies and government restrictions in response to the COVID-19 pandemic. Gross margin for the quarter was 17.4% compared to 29.3% in the same period of the prior year.
Net loss for the quarter ended June 30, 2020 was approximately $2.3 million, compared to a net loss of $232,000 for the same quarter of the prior fiscal year. Depreciation, amortization, and other non-cash expenses were $1.0 million and the Company generated positive cash flow from operating activities of $541,000 in the fourth quarter of fiscal 2020.
Fiscal Year 2020 Financial Results
Net sales for the year were $53.4 million, a decrease of $9.2 million, or 14.6%, compared to $62.6 million in the same period of the prior year. Gross profit for the year decreased $4.1 million, or 21.3%, to $15.1 million. The decrease in net sales and gross profit were primarily attributable to stay-at-home policies and government restrictions in response to the COVID-19 pandemic, as well as the continued decline in physical therapy and rehabilitation product sales. Gross margin for the year was 28.3% compared to 30.6% in the same period of the prior year. The decrease in gross margin percentage was primarily due to lower sales.
Net loss for the year ended June 30, 2020 was approximately $3.4 million, compared to a net loss of $921,000 for the year ended June 30, 2019. Depreciation, amortization, and other non-cash expenses were $2.5 million and the Company generated positive cash flow from operating activities of $3.1 million for the year.
Fiscal Year 2021 Financial Outlook
We have experienced continued positive revenue momentum in fiscal year 2021. July and August 2020 net sales are approximately 60-70% compared to the same period in fiscal year 2020.
The Company will not be providing financial guidance for the fiscal year 2021.
Conference Call
Dynatronics has scheduled a conference call for investors on September 24, 2020, at 8:30 AM ET. Those wishing to participate should call (844) 369-8770 (U.S./Canada callers) or (862) 298-0840 (international callers). A replay will be available through October 1, 2020, by dialing (877) 481-4010, Pin 36825.
About Dynatronics Corporation
Dynatronics Corporation is a leading medical device Company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and consumers. The Company’s products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Solaris™, Hausmann™, Physician’s Choice®, and PROTEAM™, among others. More information is available at www.dynatronics.com.
Safe Harbor Notification
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Those statements include references to the Company’s expectations and similar statements. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include references to our financial guidance, expected revenues, gross profit, and selling, general, and administrative expenses. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations including uncertainties involving the impact of the COVID-19 pandemic. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in the Company’s most recent filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which was filed on September 24, 2020. Dynatronics does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.
Summary Financial Results
The following is a summary of operating results for the quarters and years ended June 30, 2020 and 2019, and balance sheet highlights as of June 30, 2020 and 2019.
Summary Selected Financial Data
Statements of Operation Highlights
In thousands, except share and per share amounts
|
|
Quarter Ended | Year Ended | ||||||||||||||
|
|
June 30, | June 30, | ||||||||||||||
|
|
2020 | 2019 | 2020 | 2019 | ||||||||||||
|
|
||||||||||||||||
|
Net sales
|
$ | 8,116 | $ | 15,508 | $ | 53,409 | $ | 62,565 | ||||||||
|
Cost of sales
|
6,702 | 10,966 | 38,311 | 43,391 | ||||||||||||
|
Gross profit
|
1,414 | 4,542 | 15,098 | 19,174 | ||||||||||||
|
|
||||||||||||||||
|
Selling, general, and admin. expenses
|
3,641 | 4,883 | 18,091 | 19,970 | ||||||||||||
|
Other (expense) income, net
|
(78 | ) | (123 | ) | (442 | ) | (120 | ) | ||||||||
|
Income tax benefit (provision)
|
10 | 232 | 10 | (5 | ) | |||||||||||
|
Net loss
|
(2,295 | ) | (232 | ) | (3,425 | ) | (921 | ) | ||||||||
|
|
||||||||||||||||
|
Deemed dividend on convertible preferred stock and accretion of discount
|
– | – | (174 | ) | – | |||||||||||
|
Convertible preferred stock dividend, in common stock
|
(180 | ) | (209 | ) | (718 | ) | (795 | ) | ||||||||
|
Net loss attributable to common stockholders
|
$ | (2,475 | ) | $ | (441 | ) | $ | (4,317 | ) | $ | (1,716 | ) | ||||
|
|
||||||||||||||||
|
Net loss attributable to common stockholders per common share – basic and diluted
|
$ | (0.18 | ) | $ | (0.05 | ) | $ | (0.42 | ) | $ | (0.21 | ) | ||||
|
Weighted-average common shares outstanding – basic and diluted
|
13,461,148 | 8,509,207 | 10,262,769 | 8,246,188 | ||||||||||||
|
|
||||||||||||||||
Balance Sheet Highlights
in thousands
|
|
June 30, 2020 | June 30, 2019 | ||||||
|
Cash, cash equivalents, and restricted cash
|
$ | 2,316 | $ | 256 | ||||
|
Trade accounts receivable, net
|
4,894 | 7,495 | ||||||
|
Inventories, net
|
8,372 | 11,528 | ||||||
|
Prepaid & other
|
493 | 635 | ||||||
|
Total current assets
|
$ | 16,075 | $ | 19,914 | ||||
|
|
||||||||
|
Accounts payable
|
$ | 3,014 | $ | 3,990 | ||||
|
Accrued payroll and benefits expense
|
1,205 | 1,373 | ||||||
|
Accrued expenses
|
768 | 1,039 | ||||||
|
Other current liabilities
|
1,679 | 833 | ||||||
|
Line of credit
|
1,013 | 6,540 | ||||||
|
Current portion of acquisition earn-out liability
|
0 | 500 | ||||||
|
|
||||||||
|
Total current liabilities
|
$ | 7,679 | $ | 14,275 | ||||
CONTACT:
Dynatronics Corporation
Investor Relations
Skyler Black
(801) 676-7201
skyler.black@dynatronics.com
For additional information, please visit: www.dynatronics.com
Like Dynatronics on Facebook
Connect with Dynatronics on LinkedIn
Follow us on Twitter
SOURCE: Dynatronics Corporation
View source version on accesswire.com:
https://www.accesswire.com/607484/Dynatronics-Reports-Fourth-Quarter-and-Fiscal-Year-End-2020-Results
Former triathlon champ Claudia McCoy used the breakthrough wearable ultrasound unit to boost her recovery…
Project AED365 Aims to Empower Communities, Youth Organizations, First Responders, and more by Providing Lifesaving Automated…
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages…
This heartfelt donation demonstrates Blazesoft's commitment to corporate social responsibility with a generous gift to…
GOLETA, Calif.--(BUSINESS WIRE)--$INGN #AirwayClearance--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products…
- Revenue grew to $1,078,090, an increase of over $1million year-over-yearDallas, Georgia--(Newsfile Corp. - December…